Literature DB >> 16463434

Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors.

Yu Asanuma1, Cecilia P Chung, Annette Oeser, Ayumi Shintani, Eran Stanley, Paolo Raggi, C Michael Stein.   

Abstract

OBJECTIVE: . To examine the hypothesis that patients with systemic lupus erythematosus (SLE) have increased concentrations of interleukin-6 (IL-6), IL-8, and monocyte chemoattractant protein-1 (MCP-1) and that these cytokines are associated with coronary risk factors and atherosclerosis.
METHODS: Plasma IL-6, MCP-1, and serum IL-8 (pg/ml) concentrations were measured in 74 patients with SLE and in 85 controls. Clinical characteristics, homocysteine, lipids, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and coronary artery calcification as detected by electron beam computed tomography were measured.
RESULTS: IL-6 (13.2 +/- 13.8 pg/ml vs 6.7 +/- 3.2 pg/ml, p < 0.001) and MCP-1 (264.2 +/- 581.8 pg/ml vs 131.0 +/- 63.7 pg/ml, p < 0.001) concentrations were higher in patients with lupus than in controls. IL-8 concentrations did not differ between patients and controls (p = 0.86). In patients, IL-6 concentrations were correlated with CRP (p < 0.001), ESR (p < 0.001), SLE disease activity index (SLEDAI, p = 0.003), and body mass index (BMI, p = 0.003). IL-6 concentrations were inversely correlated with HDL cholesterol (p = 0.01). MCP-1 concentrations were correlated with SLEDAI (p = 0.01), ESR (p = 0.04), and triglycerides (p = 0.03). After controlling for age, sex, disease activity, SLICC damage index, smoking status, and systolic blood pressure, IL-6 was associated with coronary calcification (odds ratio, OR = 1.07, p = 0.035). Similar models found no association between MCP-1 or IL-8 with coronary artery calcification.
CONCLUSION: Patients with SLE have increased concentrations of IL-6 and MCP-1. These cytokines are associated with increased inflammation, BMI, and adverse lipid profiles. IL-6 is associated with burden of atherosclerosis in SLE.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16463434

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  45 in total

1.  Association between depression and vascular disease in systemic lupus erythematosus.

Authors:  Carol M Greco; Tracy Li; Abdus Sattar; Amy H Kao; Natalya Danchenko; Daniel Edmundowicz; Kim Sutton-Tyrrell; Russell P Tracy; Lewis H Kuller; Susan Manzi
Journal:  J Rheumatol       Date:  2011-12-15       Impact factor: 4.666

2.  Biomarkers of Psychological Stress in Health Disparities Research.

Authors:  Zora Djuric; Chloe E Bird; Alice Furumoto-Dawson; Garth H Rauscher; Mack T Ruffin; Raymond P Stowe; Katherine L Tucker; Christopher M Masi
Journal:  Open Biomark J       Date:  2008-01-01

3.  Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Young Hee Rho; Joseph Solus; Paolo Raggi; Annette Oeser; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

Review 4.  Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.

Authors:  Mohammed M Al Gadban; Mohamed M Alwan; Kent J Smith; Samar M Hammad
Journal:  Clin Immunol       Date:  2015-01-28       Impact factor: 3.969

5.  The homeobox transcription factor VentX controls human macrophage terminal differentiation and proinflammatory activation.

Authors:  Xiaoming Wu; Hong Gao; Weixiong Ke; Roger W Giese; Zhenglun Zhu
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

6.  Serum cystatin C is associated with kidney function but not with cardiovascular risk factors or subclinical atherosclerosis in patients with Systemic Lupus Erythematosus.

Authors:  Patricia Garcia-Garcia; Raquel Castejon; Pablo Tutor-Ureta; R A Silvestre; Susana Mellor-Pita; Carlos Jimenez-Ortiz; Miguel Yebra-Bango
Journal:  Clin Rheumatol       Date:  2017-09-15       Impact factor: 2.980

7.  Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus.

Authors:  M J Ormseth; L L Swift; S Fazio; M F Linton; P Raggi; J F Solus; A Oeser; A Bian; T Gebretsadik; A Shintani; C M Stein
Journal:  Lupus       Date:  2012-10-11       Impact factor: 2.911

8.  Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors.

Authors:  Young Hee Rho; Annette Oeser; Cecilia P Chung; Jason D Morrow; C Michael Stein
Journal:  Arch Drug Inf       Date:  2008-07

9.  Association between depression and coronary artery calcification in women with systemic lupus erythematosus.

Authors:  Carol M Greco; Amy H Kao; Abdus Sattar; Natalya Danchenko; Kathleen M Maksimowicz-McKinnon; Daniel Edmundowicz; Kim Sutton-Tyrrell; Russell P Tracy; Lewis H Kuller; Susan Manzi
Journal:  Rheumatology (Oxford)       Date:  2009-03-13       Impact factor: 7.580

10.  Atherosclerosis risk factors in systemic lupus erythematosus.

Authors:  Surabhi Agarwal; Jennifer R Elliott; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.